Can Hashimoto’s thyroiditis involve immune injury, reduced thyroid hormone production, and lower T4-to-T3 availability despite treatment?

Hashimoto’s thyroiditis is fundamentally a chronic autoimmune destructive process. The central claim is substantially supported: immune-mediated thyroid injury and declining endogenous hormone production commonly coexist, while reduced T4-to-T3 availability is a plausible—but not established universal—additional contributor in some treated patients.

Established disease biology

• Chronic lymphocytic and plasma-cell infiltration, follicular destruction, and autoreactive T-cell/cytokine-mediated thyrocyte injury are characteristic of Hashimoto’s thyroiditis.
• Loss of functioning thyroid follicles reduces endogenous T4 and T3 synthesis. Clinical expression ranges from euthyroidism to subclinical hypothyroidism (elevated TSH with normal free T4) and overt primary hypothyroidism (elevated TSH with low free T4).
• Thus, autoimmune injury and impaired hormone production are linked manifestations of the same progressive thyroid process.

T4-to-T3 availability and treatment biochemistry

• In a retrospective cohort of 408 LT4-treated patients, lower free T3 and free-T3:free-T4 ratios were seen in people with small or atrophic thyroid glands; those with larger glands had values similar to or higher than controls. This supports heterogeneity related to residual thyroid tissue rather than a universal conversion defect.
• A lower FT3:FT4 ratio can be consistent with reduced relative T3 availability, but does not directly measure deiodinase activity or tissue-level T3 action. Hashimoto-specific inflammatory inhibition of deiodinases remains mechanistically plausible but indirectly supported.
• Biochemical discordance can occur despite levothyroxine. Elevated TSH with high free T4 may result from recent dosing before blood draw, irregular adherence, impaired absorption, assay effects, or drug/food interactions—not necessarily inadequate conversion.

Clinical implications

• With intact pituitary function, TSH remains the principal LT4 titration target, generally reassessed 4–6 weeks after a dose change.
• Calcium, iron, gastrointestinal disorders, and dosing/timing issues should be addressed before changing therapy. Routine LT4/LT3 combination therapy is not recommended because benefits are inconsistent and long-term safety evidence is limited.

Bottom line

• Hashimoto’s clearly causes chronic immune thyroid injury and can impair hormone production. Reduced peripheral T4-to-T3 availability may coexist in a subset—especially LT4-treated people with little residual thyroid tissue—but should not be assumed to explain abnormal tests or persistent symptoms.